Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome

References

• Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: Results of an international prospective study. Arch Dermatol. 2002;138(8):1019–24.
   PubMedGoogle Scholar
• Harr T, French L. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J. Rare Dis. 2010;5(1):39–49. doi: 10.1186/1750-1172-5-39.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–85. PubMed PMID: 7794310. Epub 1994/11/10. eng.10.1056/NEJM199411103311906
   PubMed Web of Science ®Google Scholar
• Rzany B, Mockenhaupt M, Stocker U, et al. Incidence of Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol. 1993;129(8):1059.10.1001/archderm.1993.01680290135026
   PubMedGoogle Scholar
• Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): Use in Prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin. Infect. Dis. 1995;20(4):849–53.10.1093/clinids/20.4.849
   PubMed Web of Science ®Google Scholar
• Kura MM, Hira SK. Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization. Int J Dermatol 2001;40(7):481–4. PubMed PMID: 11679013. Epub 2001/10/27. eng.10.1046/j.1365-4362.2001.01173-7.x
   PubMed Web of Science ®Google Scholar
• Cortese LM, Soucy DM, Endy TP. Trimethoprim/sulfamethoxazole desensitization. Ann. Pharmacother. 1996 Feb;30(2):184–6. PubMed PMID: 8835054. Epub 1996/02/01. eng.
   PubMed Web of Science ®Google Scholar
• Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071–92. PubMed PMID: 9916603. Epub 1999/01/23. eng.10.1016/S0149-2918(98)80105-7
   PubMed Web of Science ®Google Scholar
• Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect. Dis. 2007;7(11):733–8.10.1016/S1473-3099(07)70262-1
   PubMed Web of Science ®Google Scholar
• Parrillo S. Stevens–Johnson syndrome and toxic epidermal necrolysis. Curr. Allergy and Asthma Rep. 2007;7(4):243–7.10.1007/s11882-007-0036-9
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Thongyen S, Chumpathat N, et al. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash. HIV Med. 2006;7(6):378–82.10.1111/hiv.2006.7.issue-6
   PubMed Web of Science ®Google Scholar
• Kiertiburanakul S, Malathum K, Watcharananan S, et al. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. Int J STD AIDS. 2009;20(3):176–9. PubMed PMID: 19255265. Epub 2009/03/04. eng.10.1258/ijsa.2008.008231
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS. 2005;19(2):185–92. PubMed PMID: 15668544. Epub 2005/01/26. eng.10.1097/00002030-200501280-00011
   PubMed Web of Science ®Google Scholar
• Saka B, Barro-Traoré F, Atadokpédé FA, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: A multicentric study in four countries. Int J Dermatol. 2013;52(5):575–79. PubMed PMID: 23330601. Epub 2013/01/22. eng.10.1111/ijd.2013.52.issue-5
   PubMed Web of Science ®Google Scholar
• Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368(9534):505–10.
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 2004;38(Supplement 2):S80–9.10.1086/381450
   Google Scholar